ERC Advanced Grant · 2022
Novel biomarkers for improving diagnostics, prognostics, and treatments of Alzheimer’s disease
Alzheimer’s disease (AD) is the most common cause of dementia and a major global health challenge. AD has a long pre-symptomatic phase spanning several decades. The accuracy of clinical AD diagnostics is mediocre, especially in primary care. This results in suboptimal treatment and care, which is especially problematic in light of emerging anti-amyloid therapies. ADVANCE-AD aims to revolutionize AD diagnostics and prognostics and fast-track the development of new effective therapies by using novel blood-based biomarkers forbeta-amyloid, tau, neurodegeneration and neuroinflammation. First, my team will transform the clinical work-up of symptomatic AD patients globally by developing…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.